(Total Views: 485)
Posted On: 10/10/2018 11:12:29 AM
Post# of 72447
End of phase 2 meeting filed with FDA
On October 10, 2018, Innovation Pharmaceuticals Inc. (the “Company”) submitted a request to the U.S. Food and Drug Administration (“FDA”) for an End-of-Phase 2 meeting regarding the Company’s oral mucositis program, to obtain FDA’s development plan guidance and review of the Company’s clinical trial of brilacidin for the indication of decreasing the incidence of severe oral mucositis in head and neck cancer patients receiving chemoradiation.
link
On October 10, 2018, Innovation Pharmaceuticals Inc. (the “Company”) submitted a request to the U.S. Food and Drug Administration (“FDA”) for an End-of-Phase 2 meeting regarding the Company’s oral mucositis program, to obtain FDA’s development plan guidance and review of the Company’s clinical trial of brilacidin for the indication of decreasing the incidence of severe oral mucositis in head and neck cancer patients receiving chemoradiation.
link
(9)
(0)
